Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Frequently asked questions
What sector does Marvel Biosciences Corp. (MBCOF) operate in?
Marvel Biosciences Corp. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Marvel Biosciences Corp. (MBCOF) current stock price?
As of the latest data, Marvel Biosciences Corp. stock price is $0.12, with a previous close of $0.11. Marvel Biosciences Corp. gained $0.00 in the last trading session, representing a 2.37% increase.
What is Marvel Biosciences Corp. (MBCOF) current market capitalization?
Marvel Biosciences Corp. market cap is approximately 7.36 million.
What is Marvel Biosciences Corp. (MBCOF) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
Does Marvel Biosciences Corp. (MBCOF) pay dividends?
No. Marvel Biosciences Corp. does not pay a dividend.
When is Marvel Biosciences Corp. (MBCOF) next earnings report?
Marvel Biosciences Corp. is expected to release its next earnings report on October 31, 2026.
What is Marvel Biosciences Corp. (MBCOF) beta (volatility) score?
Marvel Biosciences Corp. has a beta of 0.590, indicating lower volatility than the overall market.